Statin treatment is associated with a decreased risk of active tuberculosis: An analysis of a nationally representative cohort

Thorax

Volumn 71, Issue 7, 2016, Pages 646-651

  Lai, Chih Cheng ^a   Lee, Meng Tse Gabriel ^b   Lee, Shih Hao ^b   Hsu, Wan Ting ^b   Chang, Shy Shin ^c,d   Chen, Shyr Chyr ^b   Lee, Chien Chang ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; TAIWAN; TUBERCULOSIS; CASE CONTROL STUDY; MIDDLE AGED; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TAIWAN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84960869763     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207052     Document Type: Article

References (46)

1. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-Analysis of 11 randomized controlled trials involving 65, 229 participants. Arch Intern Med 2010;170:1024-31.
2. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82.
3. Auer J, Berent R, Weber T, et al. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 2002;9:1831-50.
4. Crisby M. Modulation of the inflammatory process by statins. Drugs Today 2003;39:137-43.
5. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
6. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
7. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19.
8. Crisby M. Modulation of the inflammatory process by statins. Timely Top Med Cardiovasc Dis 2005;9:E3.
9. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
10. Janda S, Young A, Fitzgerald JM, et al. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-Analysis. J Crit Care 2010;25:656.e7-22.
11. Ma Y, Wen X, Peng J, et al. Systematic review and meta-Analysis on the association between outpatient statins use and infectious disease-related mortality. PLoS ONE 2012;7:e51548.
12. Macedo AF, Taylor FC, Casas JP, et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-Analysis. BMC Med 2014;12:51.
13. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-Analysis. Arch Intern Med 2009;169:1658-67.
14. Gatfield J, Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 2000;288:1647-50.
15. Goluszko P, Nowicki B. Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells. Infect Immun 2005;73:7791-6.
16. Huynh KK, Gershenzon E, Grinstein S. Cholesterol accumulation by macrophages impairs phagosome maturation. J Biol Chem 2008;283:35745-55.
17. Miner MD, Chang JC, Pandey AK, et al. Role of cholesterol in Mycobacterium tuberculosis infection. Indian J Exp Biol 2009;47:407-11.
18. Brzostek A, Pawelczyk J, Rumijowska-Galewicz A, et al. Mycobacterium tuberculosis is able to accumulate and utilize cholesterol. J Bacteriol 2009;191:6584-91.
19. Parihar SP, Guler R, Khutlang R, et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014;209:754-63.
20. Lee MT, Lin HY, Lee SH, et al. Risk of skin ulcerations associated with oral nicorandil therapy: a population-based study. Br J Dermatol 2015;173:498-509.
21. Baker MA, Lin HH, Chang HY, et al. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012;54:818-25.
22. Chen YJ, Wu CY, Shen JL, et al. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol 2013;69:25-33.
23. Lin HH, Ezzati M, Chang HY, et al. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009;180:475-80.
24. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
25. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 2012;21(Suppl 2):138-47.
26. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res 2009;8:67-80.
27. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol 1976;104:609-20.
28. Kang YA, Choi NK, Seong JM, et al. The effects of statin use on the development of tuberculosis among patients with diabetes mellitus. Int J Tuberc Lung Dis 2014;18:717-24.
29. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
30. Falagas ME, Makris GC, Matthaiou DK, et al. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008;61:774-85.
31. Kaul D, Anand PK, Verma I. Cholesterol-sensor initiates M. Tuberculosis entry into human macrophages. Mol Cell Biochem 2004;258:219-22.
32. Pieters J. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect 2001;3:249-55.
33. Vergne I, Chua J, Lee HH, et al. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2005;102:4033-8.
34. Argmann CA, Edwards JY, Sawyez CG, et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem 2005;280:22212-21.
35. Qiu G, Hill JS. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol 2008;51:388-95.
36. Loike JD, Shabtai DY, Neuhut R, et al. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol 2004;24:2051-6.
37. Ando H, Takamura T, Ota T, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000;294:1043-6.
38. Chaudhry MZ, Wang JH, Blankson S, et al. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt) 2008;9:183-94.
39. Walzl G, Ronacher K, Hanekom W, et al. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011;11:343-54.
40. Nitta K, Akiba T, Kawashima A, et al. Characterization of TH1/TH2 profile in uremic patients. Nephron 2002;91:492-5.
41. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003;16:38-44.
42. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996;16:183-91.
43. Lai CC, Lee MT, Lee SH, et al. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis 2015;19:936-42.
44. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011;378:57-72.
45. Polgreen LA, Cook EA, Brooks JM, et al. Increased statin prescribing does not lower pneumonia risk. Clin Infect Dis 2015;60:1760-6.
46. Hoffmann P, Roumeguère T, Schulman C, et al. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006;21;355:2705-7.